| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.78 [0.67, 0.90] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.75 [0.62, 0.91] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.80 [0.66, 0.96] | | < 1 | | 0% | 1 study (1/-) | 99.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.81 [0.71, 0.92] | | < 1 | | 0% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.28 [0.80, 2.04] | | > 1 | | 68% | 2 studies (2/-) | 85.2 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.22 [0.89, 5.55] | | < 1 | | 0% | 2 studies (2/-) | 4.4 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 1.00 [0.78, 1.29] | | < 1 | | 0% | 2 studies (2/-) | 48.4 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.31 [0.61, 2.82] | | < 1 | | 57% | 2 studies (2/-) | 24.5 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.64 [0.64, 4.22] | | < 1 | | 83% | 2 studies (2/-) | 15.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.00 [0.35, 2.90] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.79 [0.55, 1.14] | | < 1 | | 0% | 1 study (1/-) | 89.5 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 0.77 [0.51, 1.15] | | < 1 | | 0% | 1 study (1/-) | 90.3 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 0.99 [0.45, 2.15] | | < 1 | | 84% | 2 studies (2/-) | 51.4 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.82 [0.33, 2.01] | | < 1 | | 86% | 2 studies (2/-) | 66.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.98 [0.66, 1.46] | | < 1 | | 0% | 2 studies (2/-) | 54.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.94 [0.65, 1.38] | | < 1 | | 59% | 2 studies (2/-) | 61.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 4.14 [1.36, 12.60] | | < 1 | | 0% | 2 studies (2/-) | 0.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 2.13 [0.68, 6.69] | | < 1 | | 81% | 2 studies (2/-) | 9.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.46 [0.27, 22.20] | | < 1 | | 82% | 2 studies (2/-) | 21.2 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 3.12 [0.29, 33.82] | | < 1 | | 0% | 2 studies (2/-) | 17.6 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.96 [0.20, 4.55] | | < 1 | | 0% | 2 studies (2/-) | 52.0 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.60 [0.41, 0.88] | | < 1 | | 0% | 2 studies (2/-) | 99.6 % | some concern | not evaluable | moderate | non important | - |
| Arthritis TRAE (grade 3-4) | 1.00 [0.02, 50.78] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 1.25 [0.33, 4.72] | | < 1 | | 0% | 2 studies (2/-) | 37.0 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 1.49 [0.11, 19.45] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.49 [0.24, 9.19] | | < 1 | | 0% | 2 studies (2/-) | 33.4 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 5.83 [0.69, 49.36] | | < 1 | | 0% | 2 studies (2/-) | 5.4 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 2.17 [0.63, 7.44] | | < 1 | | 0% | 2 studies (2/-) | 10.9 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.67 [0.19, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.72 [0.43, 1.23] | | < 1 | | 0% | 2 studies (2/-) | 88.3 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.49 [0.11, 19.45] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.49 [0.11, 19.45] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.36 [0.21, 26.89] | | < 1 | | 0% | 2 studies (2/-) | 24.7 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 6.52 [1.46, 29.18] | | < 1 | | 0% | 2 studies (2/-) | 0.7 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.08 [0.63, 1.83] | | < 1 | | 0% | 2 studies (2/-) | 39.1 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.49 [0.11, 19.45] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.39 [0.09, 1.74] | | < 1 | | 15% | 2 studies (2/-) | 89.2 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.76 [0.52, 1.11] | | < 1 | | 50% | 2 studies (2/-) | 92.4 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 1.49 [0.11, 19.45] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.50 [0.48, 13.02] | | < 1 | | 0% | 2 studies (2/-) | 13.9 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 1.00 [0.06, 16.06] | | < 1 | | 0% | 2 studies (2/-) | 49.9 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 3.12 [0.29, 33.82] | | < 1 | | 0% | 2 studies (2/-) | 17.6 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.73 [0.46, 1.17] | | < 1 | | 6% | 2 studies (2/-) | 90.2 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.00 [0.06, 16.06] | | < 1 | | 0% | 2 studies (2/-) | 49.9 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.67 [0.13, 3.54] | | < 1 | | 0% | 2 studies (2/-) | 68.0 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Alopecia AE (grade 3-4) | 1.02 [0.24, 4.29] | | < 1 | | 0% | 2 studies (2/-) | 49.2 % | some concern | not evaluable | moderate | non important | - |
| Anaemia AE (grade 3-4) | 0.56 [0.38, 0.81] | | < 1 | | 13% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 1.68 [0.61, 4.66] | | < 1 | | 0% | 2 studies (2/-) | 15.9 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 1.26 [0.18, 9.01] | | < 1 | | 0% | 2 studies (2/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Constipation AE (grade 3-4) | 2.94 [0.30, 29.05] | | < 1 | | 0% | 2 studies (2/-) | 18.0 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 2.94 [0.30, 29.05] | | < 1 | | 0% | 2 studies (2/-) | 18.0 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 1.73 [0.49, 6.11] | | < 1 | | 0% | 2 studies (2/-) | 19.9 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 1.66 [0.58, 4.68] | | < 1 | | 0% | 2 studies (2/-) | 17.2 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea AE (grade 3-4) | 1.59 [0.61, 4.12] | | < 1 | | 0% | 2 studies (2/-) | 17.2 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 1.17 [0.39, 3.52] | | < 1 | | 0% | 2 studies (2/-) | 39.0 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.82 [0.49, 1.37] | | < 1 | | 0% | 2 studies (2/-) | 78.1 % | some concern | not evaluable | moderate | non important | - |
| Headache AE (grade 3-4) | 2.01 [0.18, 22.21] | | < 1 | | 0% | 2 studies (2/-) | 28.6 % | some concern | not evaluable | moderate | non important | - |
| Hypertension AE (grade 3-4) | 7.69 [1.75, 33.81] | | < 1 | | 0% | 2 studies (2/-) | 0.4 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism AE (grade 3-4) | 1.49 [0.11, 19.45] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Increased Lipase Level AE (grade 3-4) | 1.89 [0.79, 4.52] | | < 1 | | 0% | 2 studies (2/-) | 7.6 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia AE (grade 3-4) | 1.08 [0.63, 1.83] | | < 1 | | 0% | 2 studies (2/-) | 39.1 % | some concern | not evaluable | moderate | non important | - |
| Nausea AE (grade 3-4) | 0.57 [0.13, 2.58] | | < 1 | | 39% | 2 studies (2/-) | 76.7 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.79 [0.54, 1.15] | | < 1 | | 52% | 2 studies (2/-) | 89.3 % | some concern | not evaluable | moderate | non important | - |
| Pneumonia AE (grade 3-4) | 0.78 [0.38, 1.59] | | < 1 | | 0% | 2 studies (2/-) | 75.4 % | some concern | not evaluable | moderate | non important | - |
| Pruritus AE (grade 3-4) | 1.00 [0.06, 16.06] | | < 1 | | 0% | 2 studies (2/-) | 49.9 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia AE (grade 3-4) | 0.50 [0.05, 5.53] | | < 1 | | 0% | 2 studies (2/-) | 71.3 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 3.12 [0.29, 33.82] | | < 1 | | 0% | 2 studies (2/-) | 17.6 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.76 [0.47, 1.24] | | < 1 | | 19% | 2 studies (2/-) | 86.1 % | some concern | not evaluable | moderate | non important | - |
| Vomiting AE (grade 3-4) | 0.72 [0.11, 4.67] | | < 1 | | 33% | 2 studies (2/-) | 63.6 % | some concern | not evaluable | moderate | non important | - |
